سيف الخيال وبقية الاخوه الكرام [الأرشيف]

سيف الخيال

06-11-2003, Thu 1:55 AM

ســؤال صعب الاجابة عليه اخي انور ...

وهذه نتائج التسعة شهور المنتهية والربع الثالث :

Aradigm Corporation Reports Third Quarter and Nine Month 2003 Financial Results
PR Newswire - November 05, 2003 16:02

HAYWARD, Calif., Nov 05, 2003 /PRNewswire-FirstCall via Comtex/ -- Aradigm Corporation (Nasdaq: ARDM) today announced financial results for the third quarter and nine months ended September 30, 2003.

Contract revenues for the quarter were $9.8 million, compared to $6.0 million for the same period in 2002. The majority of these revenues were derived from the collaboration agreement with Novo Nordisk A/S to develop the AERx(R) insulin Diabetes Management System (iDMS). Total operating expenses for the third quarter were $14.4 million, compared to $16.3 million for the same quarter 2002. The Company reported net loss applicable to common shareholders for the third quarter 2003 of $4.5 million, or $0.08 per share, compared with a loss of $10.3 million, or $0.34 per share, for the same period in 2002.

"The company's efforts during the quarter focused on continuing support of our ongoing AERx iDMS Phase 3 clinical trials, as well as moving our Intraject(R) program into the development phase as positive results from our configuration trial were recently announced," said Richard Thompson, Chairman and Chief Executive Officer of Aradigm. "We continue to manage our cash resources efficiently while effectively integrating the Intraject acquisition into our portfolio."

Contract revenues for the nine months ended September 30, 2003 were $26.9 million, compared with $21.4 million for the same period in 2002. Total operating expenses for the nine months ended September 30, 2003 were $46.9 million, compared with $50.5 million for the same period in 2002. The net loss for the nine months ended September 30, 2003 was $19.9 million, or $0.42 per share, compared with a net loss of $28.8 million, or $0.96 per share, for the same period in 2002.

As of September 30, 2003, cash, cash equivalents, and all investments totaled approximately $14.3 million. Immediately after the quarter end, on October 2, 2003, the company received an $8.9 million payment related to a scheduled quarterly payment and previously unreimbursed expenses for partner-funded projects. This was recorded as a receivable in the quarterly financials.

Operational Highlights

-- During the quarter, the company announced the publication of clinical
data involving the AERx Pain Management System in the peer reviewed
journal Anesthesiology. Results from this study involving 89 patients
following orthopedic bunionectomy surgery demonstrated that inhalation
of morphine via the AERx System was safe, well-tolerated and produced
comparable pain relief to intravenous morphine.
-- In September, the company announced the results from a study of its
Intraject platform showing that three configurations of the system
achieved acceptable performance, eliminating the incidence of wet
injection reported previously. Aradigm will move forward with one of
the three configurations to be then used by its potential partners.

Conference Call

The company will host a conference call and question and answer session at 4:30 pm Eastern Time, 1:30 pm Pacific Time today to discuss these financial results. Dial toll-free 1-800-559-2403 to access the conference call. International callers dial +1-847-619-6534. The event webcast can be found under the investor relations section of: www.aradigm.com. The webcast and audio replay of the conference call will be available following the call, which can be accessed on www.aradigm.com or by dialing toll-free 1-877-213-9653. International callers should dial +1-630-652-3041. The replay passcode is 7908689.

Aradigm is working to improve the quality of life for patients through the development of its innovative needle-free drug delivery platforms. The Company's AERx(R) advanced pulmonary delivery platform and its Intraject(R) needle-free injector system provide leading pharmaceutical and biotechnology partners with effective drug delivery solutions. Aradigm's technologies both use liquid drug formulations to deliver drugs to the targeted area of either the lung, or the systemic circulation. The company's most advanced product is in Phase 3 clinical trials for the treatment of diabetes in a partnership with Novo Nordisk, a world leader in diabetes care. More information about Aradigm can be found at www.aradigm.com.